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Abstract
Purpose Neovascular age-related macular degeneration
(AMD) is the main cause of central vision loss among indi-
viduals aged 50 years or older in developed countries. The aim
of this study was to review systematically the effect of
bevacizumab compared to ranibizumab in patients with
AMD at 1 year.
Methods A systematic review was performed on Medline,
Embase, and the Cochrane Library and Trial registers to
October 2013. Eligibility criteria for selecting studies were
randomised controlled trials (RCT) comparing bevacizumab
with ranibizumab in patients with neovascular AMD. Odds
ratio (OR) and mean difference (MD) estimates were synthe-
sized under fixed- and random-effects models. Heterogeneity
was assessed using the Q statistic and I2.
Results Five RCTs were included, representing 2,686
randomised patients. The meta-analysis confirmed the
non-inferiority of bevacizumab compared to ranibizumab
for change in visual acuity at 1 year (MD 0.57 letters,
−1.80 to 0.66, p=0.37, I2=0 %). Better anatomical results
were found for ranibizumab. Bevacizumab was associated
with a 34 % increase in the number of patients with at least
one serious systemic adverse event (OR 1.34, 1.08 to 1.66,
p=0.01, I2=0 %).
Conclusions The pooled evidence confirmed that, compared
with ranibizumab, bevacizumab was associated with equiva-
lent effects on visual acuity at 1 year and with a higher risk of
systemic serious adverse events. The current available data do
not show which types of adverse events occur more frequent-
ly. In practice, bevacizumab should be used under a risk-
management plan until further studies have been carried out
to assess accurately the increased risk of systemic adverse
events.
Keywords Bevacizumab . Ranibizumab . Neovascular
age-relatedmacular degeneration .Meta-analysis
Introduction
Ranibizumab, an anti-vascular endothelial growth factor (anti-
VEGF) monoclonal antibody fragment, was developed spe-
cifically to treat age-related macular degeneration (AMD) and
was approved by the Food and Drug Administration (FDA)
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and the European Agency for the Evaluation of Medicinal
Products (EMEA) in 2006 and 2007, respectively.
Nevertheless, bevacizumab, a full anti-VEGF antibody de-
rived from the same parent antibody as ranibizumab, is cur-
rently widely used off-label for AMD treatment [1].
Head-to-head studies have been performed in various
countries to establish the relative efficacy of bevacizumab
versus ranibizumab. The largest study, CATT (Comparison
of AMD Treatments Trials), demonstrated the non-inferiority
of bevacizumab versus ranibizumab on visual acuity at 1 year
[2]. In this study, serious systemic adverse events occurred
more frequently in the bevacizumab group, but this was not
observed in the other randomised trials [3–5].
In 2012, two meta-analyses including studies with a
follow-up period of 1 year were published [3, 6]. Efficacy
was studied in only one of them. Chakravarthy et al. con-
firmed the functional equivalence of the two drugs (visual
acuity) [3]. Retinal thickness at fovea was the only anatomical
efficacy criterion analysed, with more favourable results for
ranibizumab. The safety profiles for intravitreal injections of
bevacizumab and ranibizumab appeared to be similar.
Although slightly more systemic serious adverse events were
observed with bevacizumab, there were no differences be-
tween the two drugs for arterial thromboembolic events,
non-ocular haemorrhage or death [3, 6].
Since the publication of the last meta-analysis, two further
head-to-head trials have been completed [5, 4]. We, therefore,
decided to carry out a systematic review and meta-analysis in
order to update the results on the functional and anatomical
efficacy and safety profile at 1 year of bevacizumab compared
with ranibizumab in patients with neovascular AMD.
Methods
The CochraneCollaborationmethods were used to perform the
systematic review [7]. The meta-analysis was performed ac-
cording to a protocol established before the start of the litera-
ture search and data analysis. The study was conducted and
reported according to the preferred reporting items for system-
atic reviews and meta-analyses (PRISMA) checklist [8].
Eligibility criteria for considering studies for this review
To be eligible for inclusion, trials had to (1) compare the
efficacy and/or the safety of bevacizumab and ranibizumab
at 1 year (whatever the injection regimen); (2) include only
patients with AMD.
Search methods for identifying studies
The systematic search was performed on Medline (from in-
ception to October 2013), Embase (from January 2000 to
October 2013), and the Cochrane Central Register of
Controlled Trials (October 2013) using relevant text words
and medical subject headings that included all spellings of
“macular degeneration” and “bevacizumab” (Box).
Box: Trial search query
(bevacizumab[Substance Name] OR bevacizumab[TIAB]
OR Avastin[TIAB])
AND
(ranibizumab[Substance Name] OR ranibizumab[TIAB]
OR Lucentis[TIAB])
AND
(Macular Degeneration[MeSH Terms] OR Macular
Degeneration[TIAB] OR Macular Degenerations[TIAB] OR
Age-Related Maculopathies[TIAB] OR Age Related
Maculopathies[TIAB] OR Macular Dystrophy[TIAB] OR
Macular Dystrophies[TIAB] OR Age-Related Macular
Degenera t ion[TIAB] OR Age Rela t ed Macula r
Degenera t ion[TIAB] OR Age-Re la t ed Macu la r
Degenerations[TIAB] OR Age-Related Maculopathy[TIAB]
OR Age Related Maculopathy[TIAB])
AND
(“randomized controlled trial”[PT] OR “controlled clinical
trial[PT]” OR “randomized controlled trials”[MeSH Terms]
OR “random allocation”[MeSH Terms] OR “double blind
method”[MeSH Terms] OR “single-blind method”[MeSH
Terms] NOT (animal NOT human)[MeSH Terms] OR “clin-
ical trial”[PT] OR “clin* trial*”[TIAB] OR “placebos”[MeSH
Terms] OR “placebo*”[TIAB] OR “random*”[TIAB])
The search was limited to randomised clinical trials. No
language restriction was applied. We checked the reference
lists of the reviewed articles and original studies identified by
the electronic search for other potentially eligible articles.
Trial registers were also checked for unpublished studies.
Study selection
One reviewer searched the literature and assessed the quality
of trials using a standardized approach and a pre-specified
protocol.
Data collection and risk of bias assessment
One reviewer extracted data from the selected trials, and
two reviewers (ED, LH) checked these data for accuracy.
For each trial, a standard data extraction method was used
to record data on the participants’ characteristics; treatment
regimens; number of participants by group; primary out-
come, defined as change in best corrected visual acuity
(BCVA) at 1 year; anatomical efficacy parameters at base-
line and achieved at the end of the follow-up (i.e., retinal
thickness at fovea, intraretinal or subretinal fluid on OCT,
and dye leakage on angiogram); and nature and number of
serious adverse events.
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The criteria used for quality assessment were sequence
generation of allocation; allocation concealment; masking of
participants, staff, and outcome assessors; and other sources of
bias, as recommended by the Cochrane Collaboration [7].
Studies with high or unclear risk of bias for any of the first
three components were classified as low quality.
Data synthesis and analysis
The results were pooled using a random-effect model,
using the odds ratio (OR) to summarize dichotomous re-
sults and the weighted mean difference (MD) to summarize
continuous results, along with their 95 % confidence inter-
vals (CI).
Statistical heterogeneity was quantified using the I2 statistic
[9], which approximates the percentage of the total variation
(within and between studies) that is due to between-study
variation. In the absence of heterogeneity, fixed and random-
effects models yield the same results.
Potential for publication bias was explored by visually
inspecting a funnel plot of the treatment effect versus standard
error and Egger’s test.
When needed, sensitivity analysis could be performed to
determine whether some decisions had a major effect on the
results of the review.
The meta-analyses were performed using R 2.15.1 (http://
www.r-project.org) with the metafor package.
Results
Characteristics of included studies
Selection of studies
Of the 51 citations retrieved from the literature search and the
trial registers search, 10 studies were eligible. Three were
excluded as the results were not available: the Bevacizumab
Versus Ranibizumab in Age Related Macular Degeneration
AxL-2009 trial (NCT01014468, status unknown); the
Prevention of Vision loss in Patients with AMD by
Intravitreal Injection of Bevacizumab and Ranibizumab
(VIBERA, NCT00559715, status unknown); and the
Lucent is Compared to Avast in Study (LUCAS,
NCT01127360, completed). For one study, results were pre-
sented at a meeting, but no publications were retrieved (the
Comparison of Bevacizumab and Ranibizumab in Exudative
Age-Related Macular Degeneration study, BRAMD,
NTR1704; 13th EURETINA Congress, 26–29 September
2013, Hamburg).
One trial was excluded [10, 11] due to the availability of
two papers for this same trial with large discrepancies between
the two papers regarding data and results (notably the sample
size), which meant it was impossible to choose between these
two different versions.
Finally, five studies were included (Fig. 1): Subramanian
et al. [12]; the CATT study [2]; the Alternative Treatments to
Inhibit VEGF in Age-Related Choroidal Neovascularization
(IVAN) study [3]; the Multicentre Anti-VEGF Trial in Austria
(MANTA) [5]; and the French study group Avastin versus
Lucentis for Neovascular AMD (GEFAL) [4].
Methodology of the studies
Overall, two treatment regimens were identified: monthly
intravitreal injections, and as-needed (Table 1). CATT pre-
sented separate results of bevacizumab versus ranibizumab
(i) with monthly intravitreal injections and (ii) with an as-
needed regimen; therefore, it was considered as two sets of
data. Finally, six sets were included in the quantitative
analysis.
The primary outcome for all trials was defined as change in
best corrected visual acuity (BCVA) at 1 year. Three trials
were primarily designed as non-inferiority trials (CATT,
IVAN, and GEFAL); the non-inferiority margins were −5,
−3.5, and −5, respectively. The two others were considered
as superiority trials (expected difference between treatments
of seven letters for MANTA and no hypothesis defined in
Subramanian et al.).
In the GEFAL and MANTA studies, participants, investi-
gators, and outcome assessors were masked. One trial was
described as single-masked (CATT), but for the between-
treatments comparison, the investigator and assessor were
masked. For the IVAN trial, 98.6 % of the participants and
98.7 % ophthalmologists were masked at the 12-month visit.
The Subramanian et al. study was described as double-
masked, with no further details reported.
Three trials (CATT, IVAN, and GEFAL) have reported
adverse events according to the Medical Dictionary for
Regulatory Activities (MedDRA) system.
Selective outcome bias was low in all five trials regarding
visual acuity endpoints and serious adverse events (only one
trial did not provide adverse events in detail [12]).
Data analysis and synthesis
Patient characteristics
Overall, 2,686 patients were randomised to one of the two
drugs (Table 1). The baseline characteristics of patients are
presented in Table 2.
Functional endpoint (visual acuity)
The analysis population for the primary outcome consisted of
993 patients for bevacizumab and 1,028 for ranibizumab
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Fig. 1 Study identification and selection flowchart
Table 1 Characteristics of the studies included in the quantitative meta-analysis























GEFAL, 20134 Multi-centre France As-needed 255/246 Per protocol 191/183 246/239
MANTA, 20135 Multi-centre Austria As-needed 321 overall ITT 154/163* 154/163
IVAN, 20123 Multi-centre England As-needed and
Monthly
305/323 ITT 251/269 296/314
CATT (monthly), 20112 Multi-centre USA Monthly 1,208 overall ITT 265/284 286/301
CATT (as needed), 20112 Multi-centre USA As-needed ITT 271/285 300/298
Subramanian et al., 201012 Single centre USA As-needed 20/8 Available patients 15/7 20/8
ITT intention to treat
a Specific data were not available to be included in the meta-analysis
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(MANTA did not provide the mean change in BCVA in
each group and was, therefore, not included). The differ-
ence between bevacizumab and ranibizumab in terms of
mean change in BCVA at 1 year was not significant (MD
−0.57 letters, −1.80 to 0.66, p=0.37, I2=0 %; Fig. 2). The
difference was not significant for any other visual acuity
parameters.
Anatomical endpoints
Overall, ranibizumab was associated with better anatomical
outcomes (Fig. 3) in terms of change in retinal thickness at
fovea at 12 months (MD 13.77, 2.05 to 25.48, p=0.02), the
presence of intraretinal or subretinal fluid on OCT (OR 1.56,
1.29 to 1.89, p<0.01) and dye leakage on angiogram (OR
1.23, 1.02 to 1.49, p=0.03).
Adverse events
The adverse events are presented in Table 3.
Systemic (i.e. excluding ocular events) adverse event rates
were available for all the five trials. Bevacizumab was asso-
ciated with a 34 % increase in the risk of experiencing at least
one serious systemic adverse event (OR 1.34, 1.08 to 1.66, p=
0.01; Fig. 4) compared with ranibizumab, with no heteroge-
neity detected (I2=0 %). No evidence of publication bias was
suggested for this endpoint by visual inspection of funnel plots
or by Egger’s test (two-tailed p-value of 0.17). Among the
serious systemic adverse events taken individually, none were
both consistently and significantly increased (Table 3).
Infection was associated with a non-significant increase that
was relatively consistent across the trials. An increase in
gastrointestinal disorders was found with the fixed effect
model, but not with the random effect model, perhaps due to
heterogeneity.
A total of 33 ocular serious adverse events were reported in
the trials. They were not found to be different between
bevacizumab and ranibizumab (Table 3). Endophthalmitis
were reported in two trials (CATT, GEFAL) and bevacizumab
was not associated with a significant difference. Only one trial
reported a case of uveitis (IVAN).
Sensitivity analysis
We tested the robustness of our analyses by performing sen-
sitivity analyses excluding the CATT study (largest trial).
When excluding data from the two sets of CATT, the systemic
adverse effects were not statistically different between the
groups (OR 1.33, 0.95 to 1.86, p=0.09). We also performed
analyses excluding alternatively CATT monthly, CATT as
needed, GEFAL, and IVAN, thus ensuring similar sample size
in each comparison. Only analyses including one of the CATT
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Discussion
This meta-analysis, updated with the inclusion of 2013 data
from the MANTA and the GEFAL studies, did not show any
difference between bevacizumab and ranibizumab in terms of
the change in BCVA at 1 year in neovascular AMD.
The mean difference was −0.57 letters with a lower limit in
the 95 % confidence interval of −1.80 letters. This lower
bound is above all the non-inferiority margins chosen in the
non-inferiority trials ( −3.5 to −5). These results complete
those of the previous meta-analysis and support the functional
non-inferiority of bevacizumab over ranibizumab.
This meta-analysis also confirmed the trend observed in all
head-to-head studies: better anatomical results for
ranibizumab, with decrease in retinal thickness at fovea, fluid,
and dye leakage at 1 year. Results for retinal thickness at fovea
should be considered with caution since the definitions varied
between studies. The results for fluid and dye leakage have
never previously been studied in previous meta-analyses.
Further studies with longer follow-up periods would be re-
quired to confirm if the improvement in anatomical outcomes
observed with ranibizumab is maintained over time, thus
impacting on visual function and quality of life.
Concerning safety, the combined results showed a signifi-
cant increase in systemic serious adverse events of more than
30%with bevacizumab compared with ranibizumab. The two
previous meta-analyses had already reported this increase,
with relative risks for systemic adverse events of 1.35 (95 %
CI 1.05 to 1.72, 1,795 participants) [3] and 1.3 (95 %CI 1.0 to
1.7, cumulative data from CATT publication) [6] at 1 year.
The excess risk of experiencing at least one systemic
adverse event observed with bevacizumab could be surprising
for a drug administered locally. Three studies demonstrated
that the VEGF plasma level was significantly lower with
intravitreal bevacizumab than with intravitreal ranibizumab
[3, 13, 14]. VEGF is fundamental for numerous physiological
extraocular functions, but the link between a lower VEGF
serum concentration and higher serious adverse events has not
yet been proven. Understanding the mechanism by which the
systemic diffusion and action of bevacizumab occur after
intravitreal injections, and identifying the potential risk factors
associated with this mechanism, could contribute to identify-
ing which patients should be treated with caution when un-
dergoing bevacizumab intravitreal treatment.
However, serious systemic adverse events would require
more advanced analysis. Indeed, our sensitivity analyses
tended to lower the effect. Although the treatment effect size
was similar across studies, the rate of events differed between
CATT and other studies (20 % of events versus 11 %), thus
suggesting that there might be some heterogeneity.
None of the side effects of bevacizumab seen after systemic
use in the early wet AMD studies [15], especially hyperten-
sion, or the cancer studies could be confirmed in any of the
head-to-head wet AMD-studies. However, none of the five
studies included in this meta-analysis was designed or
powered to assess safety concerns.
Moreover, as no serious adverse event taken individually
was significantly increased in our analysis that included 2,625
patients (taking into account the heterogeneity), it is not pos-
sible to explain clearly this overall excess of systemic adverse
events. A safety signal could be suspected for infections. This
signal was found consistently in all the trials included in this
meta-analysis, but was not statistically significant. Given the
safety profile of systemic administrations of bevacizumab, the
recommendation could be to monitor patients closely for
infection. Especially, cases of epidemic endophthalmitis have
been previously reported, and might be increased due to
repackaging of vials of bevacizumab in single syringes in
the absence of a commercially specific packaging for intravit-
real administration. For the preparation of off-label
bevacizumab, one could recommend either the use of one vial
per patient such as in GEFAL, or, from a money-saving
perspective, an industrial repackaging in an aseptic filing
facility such as in CATT.
Fig. 2 Comparison of bevacizumab with ranibizumab for mean change in visual acuity (ETDRS letters) at 1 year. CI, confidence interval; MD, mean
difference; SD, standard deviation
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This meta-analysis is the most comprehensive review of
literature assessing the relative efficacy and safety of
bevacizumab and ranibizumab in neovascular AMD.
Despite the absence of statistical heterogeneity for most of
the outcomes studied, the selected studies were clinically
heterogeneous in terms of treatment regimens.Moreover, their
Fig. 3 Comparison of bevacizumab with ranibizumab for anatomical
results. Panel a, Change in retinal thickness at fovea at 1 year (microns);
Panel b, Presence of intraretinal or subretinal fluid on optical coherence
tomography at 1 year; Panel c, Presence of dye leakage on angiogram at
1 year. CI, confidence interval; MD, mean difference; OR, Odds ratio;
SD, standard deviation
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statistical perspectives (non-inferiority or superiority) and
populations (intention-to-treat or per protocol sets) also dif-
fered. Finally, the final BCVA value used in the analyses
varied, as some trials performed imputations for missing data
at 1 year.
However, the objective of the meta-analysis was to analyse
the effect of the treatment independently of the treatment
regimen; the duration and doses of the drugs were identical
for most of the studies. Furthermore, there was no random
error for mean change in BCVA at 1 year (primary efficacy
outcome) as no heterogeneity was found between the results
of the trials.
The analysis of safety events is also prone to several biases as
the data varied in each study in terms of quality, incidence,
severity, and adjudication. In RCTs, all SAEs must be specifical-
ly investigated and recorded regardless of the imputability with
the drug. The reporting may also be influenced by the expecta-
tions of the investigators, sponsors, and patients. However, the
definitions for safety outcomes were based on the MedDRA
system for three out of five selected trials, representing 2,280 of
Table 3 Safety results
Endpoints Number of study sets I2† (%) Fixed effect Random effect
OR [95 % CI] p value OR [95 % CI] p value
Systemic* serious adverse events 6 0 1.34 [1.08; 1.66] 0.01 1.34 [1.08; 1.66] 0.01
Gastrointestinal disorder 5 42 2.23 [1.09; 4.57] 0.03 2.19 [0.77; 6.21] 0.14
Infection 5 0 1.61 [0.99; 2.64] 0.06 1.61 [0.98; 2.64] 0.06
Nervous system disorder 5 7 1.07 [0.61; 1.87] 0.82 1.04 [0.55; 1.95] 0.91
Benign or malignant neoplasm 5 0 0.97 [0.52;1.81] 0.93 0.93 [0.49; 1.77] 0.83
Cardiac disorder 4 15 1.06 [0.66; 1.69] 0.82 1.04 [0.60; 1.78] 0.89
Myocardial infraction 5 0 0.83 [0.32; 2.10] 0.69 0.85 [0.32; 2.24] 0.74
Stroke 6 0 0.67 [0.23; 1.97] 0.47 0.76 [0.23; 2.46] 0.65
APTC arterial thromboembolic events 5 0 0.82 [0.42; 1.59] 0.55 0.89 [0.44; 1.80] 0.76
Venous thrombotic event 4 0 2.78 [0.82; 9.45] 0.10 2.38 [0.57; 9.84] 0.23
Death from any cause 6 0 1.32 [0.74; 2.36] 0.35 1.30 [0.71; 2.36] 0.39
Endophthalmitis 4 4 1.33 [0.33; 5.37] 0.69 1.37 [0.29; 6.53] 0.69
Serious non-ocular haemorrhage 2 0 3.77 [0.62; 22.90] 0.15 3.36 [0.52; 21.78] 0.20
Ocular Serious adverse events 5 57 1.78 [0.87; 3.63] 0.11 1.62 [0.49; 5.39] 0.43
APTC Antiplatelet trialist collaboration, CI confidence interval, OR odds ratio
*Excluding ocular events
†Statistical heterogeneity
Fig. 4 Comparison of bevacizumab with ranibizumab for systemic serious adverse events at 1 year. CI, confidence interval; MD, mean difference; OR,
odds ratio; SD, standard deviation
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the 2,625 patients in the safety population. Despite the explor-
atory nature of the safety analysis, no heterogeneity was ob-
served, which reinforces our results on systemic serious adverse
events as it means they cannot be imputed to artifactual data.
A further limitation to this review is that at least four more
trials comparing bevacizumab and ranibizumab for visual
acuity (primary outcome measured at 1 year) in AMD have
been identified, but at the time of our search, the results were
not published.
This meta-analysis found sufficient evidence to conclude that
bevacizumab is associated with similar effects on visual acuity
compared with ranibizumab. It also showed that bevacizumab
may be associated with an excessive risk of systemic serious
adverse events. However, the current available data do not show
which types of adverse events occur more frequently. In prac-
tice, bevacizumab for neovascular AMD should be used under a
risk management plan. The main explanation for the current use
of bevacizumab is economic, reinforced by an equivalent func-
tional efficiency with ranibizumab, but this should be balanced
against the poorer anatomical results and a suspected higher rate
of serious systemic adverse events than ranibizumab at 1 year.
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